학술논문
Efficacy and Safety of Rilzabrutinib in Patients With Chronic Spontaneous Urticaria: 12-Week Results From the RILECSU Phase 2 Dose-Ranging Study.
Document Type
Article
Author
Source
Journal of Allergy & Clinical Immunology; 2024 Supplement, Vol. 153 Issue 2, pAB373-AB373, 1p
Subject
Language
ISSN
00916749